Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Top Cited Papers
Open Access
- 27 April 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 22 (6), 765-778
- https://doi.org/10.1016/s1470-2045(21)00213-8
Abstract
No abstract availableFunding Information
- Cancer Research UK
This publication has 24 references indexed in Scilit:
- A dynamic COVID-19 immune signature includes associations with poor prognosisNature Medicine, 2020
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- Approaches and Challenges in SARS-CoV-2 Vaccine DevelopmentCell Host & Microbe, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreakEuropean Journal of Clinical Investigation, 2020
- COVID-19 in cancer patients: risk, clinical features, and managementCancer Biology & Medicine, 2020
- Immune regulation by glucocorticoids can be linked to cell type–dependent transcriptional responsesThe Journal of Experimental Medicine, 2019
- Efficacy of the Influenza Vaccine in Patients with Malignant LymphomaClinical Medicine & Research, 2005
- Cancer Patients Undergoing Chemotherapy Show Adequate Serological Response to Vaccinations Against Influenza Virus and Streptococcus pneumoniaeMedical Oncology, 2002
- Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapyEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993